How does the Extracellular Matrix Change in the Setting of Heart Failure?
The Extracellular Matrix is a dynamic entity, showing constant degradation and deposition while providing the framework for the cardiomyocytes and interstitial proteins to lie on. Its function is important for the proper myocyte alignment within the heart and for internal communication from cell to matrix. Dysregulation of the remodeling process resulting in the breakdown of collagen by matrix metalloproteinases is a hallmark of heart failure pathophysiology and produces functional changes encompassing all matrix proteins. Several etiologies with distinct mechanisms ultimately bring about signs of heart exhaustion such as reduced ejection fraction, reduced compliance and ventricular dilatation. Discussed in this paper is the role of inflammation, collagen cross-linking and of myofibroblasts in matrix dysfunction and the mechanisms with which these changes occur in heart failure. Understanding extracellular protein roles within this context would allow for specific drug targeting and thus prevention of heart failure in the early stages of the disease. More studies must be conducted to discover the specific matrix proteins and cytokines that modulate the pathological remodeling process. Serum biomarkers of extracellular degradation products, selective metalloproteinase inhibitors and a personalized treatment approach with a revisal of the current classification of heart failure are topics requiring further exploration.
Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015; Feb 28 385(9970): 812-24.
Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012; Jan 25 344: d8059.
Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ, et al. The national heart failure audit for England and Wales 2008-2009. Heart. 2011; Jun 97(11): 876-86.
Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 2005; Jan 1 65(1): 40-51.
Meschiari CA, Ero OK, Pan H, Finkel T, Lindsey ML. The impact of aging on cardiac extracellular matrix. Geroscience. 2017; Feb 39(1): 7-18.
Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; Jul 18 114(3): 216-25.
Lindsey ML, Hall ME, Harmancey R, Ma Y. Adapting extracellular matrix proteomics for clinical studies on cardiac remodeling post-myocardial infarction. Clin Proteomics. 2016; 13: 19.
Eckhouse SR, Spinale FG. Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012; Jan 8(1): 7-20.
Fomovsky GM, Thomopoulos S, Holmes JW. Contribution of extracellular matrix to the mechanical properties of the heart. J Mol Cell Cardiol. 2010; Mar 48(3): 490-6.
Parker KK, Ingber DE. Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering. Philos Trans R Soc Lond B Biol Sci. 2007; Aug 29 362(1484): 1267-79.
Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin. 2000; Aug 18(3): 435-42.
Kitamura M, Shimizu M, Ino H, Okeie K, Yamaguchi M, Fujno N, et al. Collagen remodeling and cardiac dysfunction in patients with hypertrophic cardiomyopathy: the significance of type III and VI collagens. Clin Cardiol. 2001; Apr 24(4): 325-9.
Lodish H BA, Zipursky SL et al. Molecular Cell Biology. 4th ed. New York: W.H. Freeman; 2000. Section 22.3: Collagen: The Fibrous Proteins of the Matrix p.
Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol (Paris). 2005; Sep 53(7): 430-42.
Holmes DF, Graham HK, Trotter JA, Kadler KE. STEM/TEM studies of collagen fibril assembly. Micron. 2001; Apr 32(3): 273-85.
Kato S, Spinale FG, Tanaka R, Johnson W, Cooper Gt, Zile MR. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol. 1995; Sep 269(3 Pt 2): H863-8.
Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res. 2009; Dec 4 105(12): 1164-76.
McCurdy S, Baicu CF, Heymans S, Bradshaw AD. Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol. 2010; Mar 48(3): 544-9.
Votteler M, Berrio DA, Horke A, Sabatier L, Reinhardt DP, Nsair A, et al. Elastogenesis at the onset of human cardiac valve development. Development. 2013; Jun 140(11): 2345-53.
Mithieux SM, Weiss AS. Elastin. Adv Protein Chem. 2005; 70: 437-61.
Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, et al. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J. 1999; May 15 340 (Pt 1): 171-81.
Bowers SL, Banerjee I, Baudino TA. The extracellular matrix: at the center of it all. J Mol Cell Cardiol. 2010; Mar 48(3): 474-82.
Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg. 2006; Oct 30(4): 604-10.
Ma Y, Halade GV, Lindsey ML. Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res. 2012; Dec 5(6): 848-57.
Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010; Sep 11(9): 633-43.
Hegarova M, Kautzner J. Changes in the extracellular matrix during myocardial remodelling. Curr Res Cardiol. 2015; 2: 35-9.
Bruggink AH, van Oosterhout MF, de Jonge N, Cleutjens JP, van Wichen DF, van Kuik J, et al. Type IV collagen degradation in the myocardial basement membrane after unloading of the failing heart by a left ventricular assist device. Lab Invest. 2007; Nov 87(11): 1125-37.
Shai SY, Harpf AE, Ross RS. Integrins and the myocardium. Genet Eng. 2002;24:87-105.
Ross RS, Borg TK. Integrins and the myocardium. Circ Res. 2001 Jun; 88(11):1112-9.
Ding B, Price RL, Goldsmith EC, Borg TK, Yan X, Douglas PS, et al. Left ventricular hypertrophy in ascending aortic stenosis mice: anoikis and the progression to early failure. Circulation. 2000; Jun 20 101(24): 2854-62.
Hornberger LK, Singhroy S, Cavalle-Garrido T, Tsang W, Keeley F, Rabinovitch M. Synthesis of extracellular matrix and adhesion through beta(1) integrins are critical for fetal ventricular myocyte proliferation. Circ Res. 2000; Sep 15 87(6): 508-15.
Sharma A, Askari JA, Humphries MJ, Jones EY, Stuart DI. Crystal structure of a heparin- and integrin-binding segment of human fibronectin. EMBO J. 1999; Mar 15 18(6): 1468-79.
Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014; Feb 28 114(5): 872-88.
Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001; May 107(9): 1049-54.
de Castro Bras LE, Toba H, Baicu CF, Zile MR, Weintraub ST, Lindsey ML, et al. Age and SPARC change the extracellular matrix composition of the left ventricle. Biomed Res Int. 2014; 2014: 810562.
Lindsey ML, Iyer RP, Jung M, DeLeon-Pennell KY, Ma Y. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. J Mol Cell Cardiol. 2016; Feb 91: 134-40.
Graham HK, Trafford AW. Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. Am J Physiol Heart Circ Physiol. 2007; Mar 292(3): H1364-72.
Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol. 1996; Jul 28(7): 1415-28.
Lindsey ML. MMP induction and inhibition in myocardial infarction. Heart Fail Rev. 2004; Jan 9(1): 7-19.
Spinale FG. Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart. Circulation Research. 2002; 90(5): 520-30.
Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail. 1999; Dec 1(4): 337-52.
Hutchinson KR, Stewart JA, Jr., Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol. 2010; Mar 48(3): 564-9.
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; Feb 15 69(3): 562-73.
Horn MA, Trafford AW. Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol. 2016; Apr 93: 175-85.
Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail. 2008; Aug 14(6):467-74.
Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev. 2012; Sep 17(4-5): 693-706.
Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord. 2003; Mar 3(1): 1-30.
Caterina NC, Windsor LJ, Bodden MK, Yermovsky AE, Taylor KB, Birkedal-Hansen H, et al. Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1). Biochim Biophys Acta. 1998; Oct 14 1388(1): 21-34.
Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998 Oct;98(17):1728-34.
Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009; Mar-Apr 17(2): 153-62.
Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf). 2008; Sep 194(1): 3-21.
Suthahar N, Meijers WC, Sillje HHW, de Boer RA. From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. Curr Heart Fail Rep. 2017; Aug 14(4): 235-50.
Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011; Jan 4(1): 44-52.
DeLeon-Pennell KY, Meschiari CA, Jung M, Lindsey ML. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Prog Mol Biol Transl Sci. 2017; 147: 75-100.
Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012; Sep 3 5(1): 15.
Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest. 2000; Oct 106(7): 857-66.
Miner EC, Miller WL. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc. 2006; Jan 81(1): 71-6.
Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002; Dec 13 91(12): 1103-13.
Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011; Apr 57(4): 376-9.
Franssen C, Gonzalez Miqueo A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J. 2016; Apr 24(4): 259-67.
Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002; Apr 282(4): H1288-95.
Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol. 2011; Jan-Feb 52(1): 30-40.
Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. J Nucl Cardiol. 2001; Mar-Apr 8(2): 188-96.
Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006; Feb 15 69(3): 666-76.
Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008; Feb 233(2): 109-22.
Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000; May 46(2): 250-6.
Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 2002; Feb 39(2): 258-63.
Davis J, Molkentin JD. Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol. 2014; May 70: 9-18.
Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007; Mar 127(3): 526-37.
Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 2002; Mar 27(2): 92-8.
Sanderson JE. Diastolic heart failure and the extracellular matrix. Int J Cardiol. 1997; Dec 1 62 Suppl 1: S19-21.
van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010; Jan 7(1): 30-7.
van Amerongen MJ, Bou-Gharios G, Popa E, van Ark J, Petersen AH, van Dam GM, et al. Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol. 2008; Feb 214(3): 377-86.
Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A. 2006; Nov 28 103(48): 18284-9.
Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant. 2003; 7 Suppl 3: 86-8.
Lopez B, Ravassa S, Gonzalez A, Zubillaga E, Bonavila C, Berges M, et al. Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. J Am Coll Cardiol. 2016; Jan 26 67(3): 251-60.
Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing Dev. 2001; May 31 122(7): 735-55.
Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007; Dec 9(12): 1146-55.
Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF, Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996; May 148(5): 1639-48.
van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; Sep 19 48(6): 1217-24.
Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail. 2007; Aug 9(8): 776-86.
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000; Nov 28 102(22):2700-6.
Lopez B, Gonzalez A, Ravassa S, Beaumont J, Moreno MU, San Jose G, et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. J Am Coll Cardiol. 2015; Jun 9 65(22): 2449-56.
Tziakas DN, Chalikias GK, Stakos D, Chatzikyriakou SV, Papazoglou D, Mitrousi K, et al. Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur J Prev Cardiol. 2012; Feb 19(1): 62-71.
Kato TS, Chokshi A, Singh P, Khawaja T, Iwata S, Homma S, et al. Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure. J Heart Lung Transplant. 2012; Jan 31(1): 37-45.
Kupari M, Laine M, Turto H, Lommi J, Werkkala K. Circulating collagen metabolites, myocardial fibrosis and heart failure in aortic valve stenosis. J Heart Valve Dis. 2013; Mar 22(2): 166-76.
van Kimmenade RR, Januzzi JL, Jr. Emerging biomarkers in heart failure. Clin Chem. 2012; Jan 58(1): 127-38.
Jones K, Saxon L, Cunningham W, Adams P, Guideline Development G. Secondary prevention for patients after a myocardial infarction: summary of updated NICE guidance. BMJ. 2013; Nov 13 347: f6544.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; Sep 11 371(11): 993-1004.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008; Oct 10(10): 933-89.
Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 1996; Feb 9 155(1): 13-21.
Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res. 1999; Sep 43(4): 838-49.
Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003; Oct 7 108(14): 1753-9.
Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006; Jul 4 48(1): 15-20.
Jugdutt BI, Jelani A, Palaniyappan A, Idikio H, Uweira RE, Menon V, et al. Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker. Circulation. 2010; Jul 27 122(4): 341-51.
McAloon CJ, Ali D, Hamborg T, Banerjee P, O'Hare P, Randeva H, et al. Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review. Open Heart. 2017; 4(2): e000639.
Zamilpa R, Lindsey ML. Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol. 2010; Mar 48(3): 558-63.
Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension. 2004; Jun 43(6): 1195-201.
Mavroidis M, Capetanaki Y. Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy. Am J Pathol. 2002; Mar 160(3): 943-52.
Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1997; Dec 1(1): 13-23.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 May 2;92(8): 827-39.
Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; Oct 87(4): 1285-342.
Tyagi SC. Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovasc Pathol. 1998; May-Jun 7(3): 153-9.
Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 2011; Mar 50(3): 522-33.
Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007; Mar 117(3): 568-75.
Copyright (c) 2018 Amerikos Argyriou
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to firstname.lastname@example.org
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to email@example.com